Form 4: Greenwich LifeSciences CEO Snehal Patel Acquires 3,600 Shares of Common Stock
SEC Form 4 Filing
Greenwich LifeSciences CEO Snehal Patel reports the acquisition of 3,600 shares of common stock at a price of $9.1 per share on April 7, 2025.
Summary
- On April 7, 2025, Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc., acquired 3,600 shares of common stock.
- The purchase price was $9.1 per share.
- Following the transaction, Patel directly owns 5,561,602 shares of Greenwich LifeSciences, Inc.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The CEO buying shares is generally seen as a positive, but without more context, it's difficult to gauge the significance.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date of transaction: Snehal Patel acquired 3,600 shares of common stock. |
| 04/08/2025 | Date of signature on the Form 4 filing. |
Keywords
Greenwich LifeSciences, GLSI, Snehal Patel, Stock Acquisition, Form 4, Beneficial Ownership, CEO, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.